1. Home
  2. RGT vs BDTX Comparison

RGT vs BDTX Comparison

Compare RGT & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Royce Global Value Trust Inc.

RGT

Royce Global Value Trust Inc.

N/A

Current Price

$14.16

Market Cap

94.4M

Sector

Finance

ML Signal

N/A

Logo Black Diamond Therapeutics Inc.

BDTX

Black Diamond Therapeutics Inc.

SELL

Current Price

$1.32

Market Cap

104.0M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
RGT
BDTX
Founded
1986
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
94.4M
104.0M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
RGT
BDTX
Price
$14.16
$1.32
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
★ $11.00
AVG Volume (30 Days)
15.3K
★ 688.1K
Earning Date
01-01-0001
11-10-2026
Dividend Yield
★ 1.43%
N/A
EPS Growth
N/A
★ 130.71
EPS
★ 0.92
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$15.58
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.19
$1.35
52 Week High
$15.79
$3.97

Technical Indicators

Market Signals
Indicator
RGT
BDTX
Relative Strength Index (RSI) 39.44 33.86
Support Level $14.04 N/A
Resistance Level $14.80 $1.94
Average True Range (ATR) 0.30 0.14
MACD -0.08 -0.03
Stochastic Oscillator 0.00 3.08

Price Performance

Historical Comparison
RGT
BDTX

About RGT Royce Global Value Trust Inc.

Royce Global Value Trust Inc is a diversified closed-end investment company. The Fund spreads its investments across diversified sectors such as information technology, consumer discretionary, health care, materials, consumer staples and energy. Geographically, it has presence in the United Kingdom, Japan, the United States, Canada, France, Hong Kong and Germany.

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

Share on Social Networks: